You are here:

cladribine (Mavenclad)

Advice

Following a full submission:

cladribine (Mavenclad®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.

SMC restriction:

  • Patients with rapidly evolving severe relapsing-remitting MS: patients with two or more relapses in the prior year whether on treatment or not, and at least one T1 gadolinium-enhancing lesion.
  •  Patients with sub-optimal therapy relapsing-remitting MS: patients with one or more relapses in the previous year while on disease modifying therapy, and at least one T1 gadolinium-enhancing lesion or nine T2 lesions.

In a phase III study cladribine showed superiority over placebo in terms of annualised relapse rate in patients with high disease activity relapsing-remitting multiple sclerosis.

Drug Details

Drug Name: cladribine (Mavenclad)
SMC Drug ID: 1300/18
Manufacturer: Merck
Indication: Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 12 February 2018

Back